Agreed dunover, positive pointers except for negligible Evolis sales. We were led to believe almost a decade ago that US sales would reach $100m within 7 years.
Evolis should still be the main brand to promote given its unique hair care features and huge target global market.
Yet the incumbent management continues its flawed obsession on excess M&A. Question why the quest for in house M&A deals now apparently its default stock in trade with beauty products simply camouflage and AN1 as a mere play thing.
Wow, they’ve finally realised the need for a Director of Strategy……part time! The expectation for the grant of 1,000,000 options is a lift in sp to 6 cents.Hopefully that at least arrests the slide in sp having halved and halved again multiple times in recent years.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.481M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 1293665 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 332362 | 2 |
View Market Depth
| Last trade - 16.30pm 25/07/2025 (20 minute delay) ? |
| AN1 (ASX) Chart |
Day chart unavailable